Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F13%3A%230002087" target="_blank" >RIV/65269705:_____/13:#0002087 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/13:A14019L5

Result on the web

<a href="http://dx.doi.org/10.1016/S1470-2045(13)70398-X" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(13)70398-X</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1470-2045(13)70398-X" target="_blank" >10.1016/S1470-2045(13)70398-X</a>

Result language

angličtina

Original language name

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

Original language description

We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of patients with relapsed or refractory multiple myeloma. Methods In our randomised, double-blind, placebo-controlled, phase 3 trial, we enrolled adults (= 18 years) at 174 university hospitals in 31 countries worldwide. Eligible patients had to have non-refractory multiple myeloma that previously responded to treatment (one to three regimens) but were currently progressing, ECOG performance statusesof 2 or less, and no continuing toxic effects from previous treatment. We excluded patients with known resistance to bortezomib. We randomly allocated patients (1: 1) using an interactive voice response system to receive 21 day cycles of bortezomib (1 .3 mg/m(2) intravenously on days 1, 4, 8, and 11) in combination with oral vorinostat (400 mg) or matching placebo once-daily on days 1-14..

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

The Lancet Oncology

ISSN

1470-2045

e-ISSN

—

Volume of the periodical

14

Issue of the periodical within the volume

11

Country of publishing house

US - UNITED STATES

Number of pages

12

Pages from-to

1129-1140

UT code for WoS article

000325091900046

EID of the result in the Scopus database

—